AR070073A1 - Derivados de imidazo[1, 2 - a]piridin-2-carboxamidas, intermediarios para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades que implican a los receptores not. - Google Patents
Derivados de imidazo[1, 2 - a]piridin-2-carboxamidas, intermediarios para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades que implican a los receptores not.Info
- Publication number
- AR070073A1 AR070073A1 ARP080105778A ARP080105778A AR070073A1 AR 070073 A1 AR070073 A1 AR 070073A1 AR P080105778 A ARP080105778 A AR P080105778A AR P080105778 A ARP080105778 A AR P080105778A AR 070073 A1 AR070073 A1 AR 070073A1
- Authority
- AR
- Argentina
- Prior art keywords
- imidazo
- pyridin
- pyridine
- ethyl
- carboxylic acid
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical class C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 9
- 125000005843 halogen group Chemical group 0.000 abstract 9
- 229910003827 NRaRb Inorganic materials 0.000 abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- FQYYIPZPELSLDK-UHFFFAOYSA-N ethyl pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC=N1 FQYYIPZPELSLDK-UHFFFAOYSA-N 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- -1 saturated cyclic amine Chemical class 0.000 abstract 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 abstract 2
- DZIGPBORHYBQNT-UHFFFAOYSA-N 6-(1,3-oxazol-2-yl)imidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound C1=CC2=NC(C(=O)O)=CN2C=C1C1=NC=CO1 DZIGPBORHYBQNT-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 abstract 1
- XDNFEJPWYLNZMZ-UHFFFAOYSA-N 2,3-dihydroindol-1-yl-(5-methylimidazo[1,2-a]pyridin-2-yl)methanone Chemical compound C1CC2=CC=CC=C2N1C(=O)C1=CN2C(C)=CC=CC2=N1 XDNFEJPWYLNZMZ-UHFFFAOYSA-N 0.000 abstract 1
- INTNEELQXPKMNM-UHFFFAOYSA-N 3-ethylpyridine-2-carboxylic acid Chemical compound CCC1=CC=CN=C1C(O)=O INTNEELQXPKMNM-UHFFFAOYSA-N 0.000 abstract 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- KCBLSJZZGWEYLT-UHFFFAOYSA-N 6-(1-tritylimidazol-4-yl)imidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound C1=CC2=NC(C(=O)O)=CN2C=C1C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KCBLSJZZGWEYLT-UHFFFAOYSA-N 0.000 abstract 1
- LMRFFCNAPPYYJV-UHFFFAOYSA-N 6-(1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound C1=CC2=NC(C(=O)O)=CN2C=C1C=1C=CNN=1 LMRFFCNAPPYYJV-UHFFFAOYSA-N 0.000 abstract 1
- NAIBHYWVJCQWHO-UHFFFAOYSA-N 6-(1h-pyrrol-3-yl)imidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound C1=CC2=NC(C(=O)O)=CN2C=C1C=1C=CNC=1 NAIBHYWVJCQWHO-UHFFFAOYSA-N 0.000 abstract 1
- FMRCUZIBHZXHNK-UHFFFAOYSA-N 6-(2h-triazol-4-yl)imidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound C1=CC2=NC(C(=O)O)=CN2C=C1C1=CNN=N1 FMRCUZIBHZXHNK-UHFFFAOYSA-N 0.000 abstract 1
- UTTHZCRZRMHPMI-UHFFFAOYSA-N 6-(furan-2-yl)imidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound C1=CC2=NC(C(=O)O)=CN2C=C1C1=CC=CO1 UTTHZCRZRMHPMI-UHFFFAOYSA-N 0.000 abstract 1
- KRYFQISDBUVDJF-UHFFFAOYSA-N 6-(furan-3-yl)imidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound C1=CC2=NC(C(=O)O)=CN2C=C1C=1C=COC=1 KRYFQISDBUVDJF-UHFFFAOYSA-N 0.000 abstract 1
- BJNFFGIXWPYPSN-UHFFFAOYSA-N 6-[3-(hydroxymethyl)phenyl]imidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound OCC1=CC=CC(C2=CN3C=C(N=C3C=C2)C(O)=O)=C1 BJNFFGIXWPYPSN-UHFFFAOYSA-N 0.000 abstract 1
- ICPHWBWBUHXEJO-UHFFFAOYSA-N 6-[6-[(2-methylpropan-2-yl)oxycarbonylamino]pyridin-2-yl]imidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(C2=CN3C=C(N=C3C=C2)C(O)=O)=N1 ICPHWBWBUHXEJO-UHFFFAOYSA-N 0.000 abstract 1
- KVWQCSAJCUROAZ-UHFFFAOYSA-N 6-methoxy-5-methylimidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound CC1=C(OC)C=CC2=NC(C(O)=O)=CN21 KVWQCSAJCUROAZ-UHFFFAOYSA-N 0.000 abstract 1
- UTRHHBXFIAIQFN-UHFFFAOYSA-N 6-pyridin-2-ylimidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound C1=CC2=NC(C(=O)O)=CN2C=C1C1=CC=CC=N1 UTRHHBXFIAIQFN-UHFFFAOYSA-N 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 125000004666 alkoxyiminoalkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- GORHSKVFLXBPIL-UHFFFAOYSA-N ethyl 6-(1-tritylimidazol-4-yl)imidazo[1,2-a]pyridine-2-carboxylate Chemical compound C1=CC2=NC(C(=O)OCC)=CN2C=C1C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 GORHSKVFLXBPIL-UHFFFAOYSA-N 0.000 abstract 1
- JTZCSKOZRQXJIQ-UHFFFAOYSA-N ethyl 6-(1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-2-carboxylate Chemical compound C1=CC2=NC(C(=O)OCC)=CN2C=C1C=1C=CNN=1 JTZCSKOZRQXJIQ-UHFFFAOYSA-N 0.000 abstract 1
- XPYHBXVJLCXYGI-UHFFFAOYSA-N ethyl 6-(2h-triazol-4-yl)imidazo[1,2-a]pyridine-2-carboxylate Chemical compound C1=CC2=NC(C(=O)OCC)=CN2C=C1C1=CNN=N1 XPYHBXVJLCXYGI-UHFFFAOYSA-N 0.000 abstract 1
- HSUGROQEAOLMSU-UHFFFAOYSA-N ethyl 6-(furan-2-yl)imidazo[1,2-a]pyridine-2-carboxylate Chemical compound C1=CC2=NC(C(=O)OCC)=CN2C=C1C1=CC=CO1 HSUGROQEAOLMSU-UHFFFAOYSA-N 0.000 abstract 1
- IMBADWUCIGILRT-UHFFFAOYSA-N ethyl 6-[3-(hydroxymethyl)phenyl]imidazo[1,2-a]pyridine-2-carboxylate Chemical compound C1=CC2=NC(C(=O)OCC)=CN2C=C1C1=CC=CC(CO)=C1 IMBADWUCIGILRT-UHFFFAOYSA-N 0.000 abstract 1
- XVQAIQCRFRCNOV-UHFFFAOYSA-N ethyl 6-methoxy-5-methylimidazo[1,2-a]pyridine-2-carboxylate Chemical class CC1=C(OC)C=CC2=NC(C(=O)OCC)=CN21 XVQAIQCRFRCNOV-UHFFFAOYSA-N 0.000 abstract 1
- LTTCCMABTWTJAD-UHFFFAOYSA-N ethyl 6-pyridin-2-ylimidazo[1,2-a]pyridine-2-carboxylate Chemical compound C1=CC2=NC(C(=O)OCC)=CN2C=C1C1=CC=CC=N1 LTTCCMABTWTJAD-UHFFFAOYSA-N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- BEHYAANJUKYBTH-UHFFFAOYSA-N imidazo[1,2-a]pyridine-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=CN21 BEHYAANJUKYBTH-UHFFFAOYSA-N 0.000 abstract 1
- WQLJLPDGSLZYEP-UHFFFAOYSA-M imidazo[1,2-a]pyridine-2-carboxylate Chemical compound C1=CC=CC2=NC(C(=O)[O-])=CN21 WQLJLPDGSLZYEP-UHFFFAOYSA-M 0.000 abstract 1
- WQLJLPDGSLZYEP-UHFFFAOYSA-N imidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CN21 WQLJLPDGSLZYEP-UHFFFAOYSA-N 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Derivados de imidazo [1,2-a]-piridin-2-carboxamidas, intermediarios para su síntesis, una composicion farmacéutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades psiquiátricas, neurodegenerativas, inflamatorias, osteoporosis y cánceres. Reivindicacion 1: Compuestos de formula (1) en la que: X e Y forman, con el átomo de nitrogeno al que están enlazados, una amina cíclica mono o bicíclica, saturada o parcialmente saturada, de 5 a 10 eslabones, que opcionalmente incluye 1 a 4 heteroátomos suplementarios escogidos entre O, S, N, opcionalmente sustituida por un átomo de halogeno, un grupo alquilo C1-6, alcoxi C1-6, ciano, NRaRb o COOR8, estando dichos grupos alquilo C1-6 y alcoxi C1-6 opcionalmente sustituidos por uno o varios átomos de halogeno; R1 representa un átomo de hidrogeno, un átomo de halogeno, un grupo alcoxi C1-6, alquilo C1-6 o NRcRd, pudiendo los grupos alquilo y alcoxi estar opcionalmente sustituidos por uno o varios átomos de halogeno, un grupo hidroxi, amino o alcoxi C1-6; R2 representa uno de los grupos siguientes: un átomo de hidrogeno, un grupo alquilo C1-6 opcionalmente sustituido por uno o varios grupos escogidos independientemente entre sí entre un grupo hidroxi, un átomo de halogeno, un grupo NRaRb, alcoxi C1-6 o fenilo, alcoxi C1-6 opcionalmente sustituido por uno o varios grupos escogidos independientemente entre sí entre un hidroxi, un átomo de halogeno, un grupo NRaRb, alquenilo C2-6, alquinilo C2-6, -CO-R5, -CO-NR6R7, -CO-O-R8, -NR9-CO-R10, -N=CH-NRaRb, NR11R12, un átomo de halogeno, un grupo ciano, nitro, hidroxiiminoalquilo, alcoxiiminoalquilo, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, (alquil C1-6)3sililetinilo, -SO2-NR9R10, fenilo opcionalmente sustituido por uno o varios grupos escogidos independientemente entre sí entre los átomos o grupos siguientes: halogeno, alcoxi C1-6, ciano, NRaRb, -CO-R5, -CO-NR6R7, -CO-O-R8, alquilo C1-6 opcionalmente sustituido por uno o varios hidroxi o NRaRb, un grupo heterocíclico opcionalmente sustituido por un átomo de halogeno, alquilo C1-6, alcoxi C1-6, ciano, NRaRb, COOR8, estando los grupos alquilo C1-6 y alcoxi C1-6 opcionalmente sustituidos por uno o varios átomos de halogeno o hidroxi; R3 representa un átomo de hidrogeno, un grupo alquilo C2-6, alcoxi C1-6 o un átomo de halogeno; R4 representa un átomo de hidrogeno, un grupo alquilo C1-4, alcoxi C1-4 o un átomo de fluor; R5 representa un átomo de hidrogeno, un grupo fenilo o un grupo alquilo C1-6; R6 y R7, idénticos o diferentes, representan un átomo de hidrogeno, un grupo alquilo C1-6 o forman con el átomo de nitrogeno al que están enlazados un ciclo de 4 a 7 eslabones que incluye opcionalmente otro heteroátomo escogido entre N, O o S; R8 representa un grupo alquilo C1-6; R9 y R10, idénticos o diferentes, representan un átomo de hidrogeno o un grupo alquilo C1-6; R11 y R12, idénticos o diferentes, representan un átomo de hidrogeno o un grupo alquilo C1-6; Ra y Rb son independientemente entre sí hidrogeno, alquilo C1-6 o forman con el átomo de nitrogeno al que están enlazados un ciclo de 4 a 7 eslabones; Rc es hidrogeno y Rd es alquilo C1-6; con excepcion de 2-(2,3-dihidro-1H-indol-1-ilcarbonil)-5-metilimidazo[1,2-a]piridina y de 2-(4-tiomorfolin-1-il-carbonil)-6-cloroimidazo[1,2-a]-piridina en estado de base o de sal de adicion a un ácido. Reivindicacion 19: Compuestos 6-Metoxi-5-metilimidazo[1,2-a]piridin-2-carboxilato de etilo; Ácido 6-metoxi-5-metilimidazo[1,2-a]piridin-2-carboxílico; 6-(3-Hidroximetil-fenil)-imidazo[1,2-a]piridin-2-carboxilato de etilo; Ácido 6-(3-hidroximetil-fenil)-imidazo[1,2-a]piridin-2-carboxílico; 6-(6-{[(1,1-DimetiIetoxi)carbonil]amino}piridin-2-il)imidazo[1,2-a]piridin-2-carboxilato de etilo; Ácido 6-(6-{[(1,1-dimetiletoxi)carbonil}amino}piridin-2-il)imidazo[1,2-a]piridin-2-carboxílico; (6-Piridin-2-il)-imidazo[1,2-a]piridin-2-carboxilato de etilo; Ácido 6-(piridin-2-il)-imidazo[1,2-a]piridin-2-carboxílico; 6-(1-Trifenilmetil-1H-imidazol-4-il)imidazo[1,2-a]piridin-2-carboxilato de etilo; Ácido 6-(1-Trifenilmetil-1H-imidazol-4-il)imidazo[1,2-a]piridin-2-carboxílico, 6-[1-(Triisopropilsilil)-1H-pirrol-3-il]imidazo[1,2-a]piridin-2-carboxilato de etilo; Ácido 6-(1H-pirrol-3-il)imidazo[1,2-a]piridin-2-carboxílico; 6-(1H-pirazol-3-il)-imidazo[1,2-a]piridin-2-carboxilato de etilo; Ácido 6-(1H-pirazol-3-il)imidazo[1,2-a]piridin-2-carboxílico; 6-(Furan-2-il)-imidazo[1,2-a]piridin-2-carboxilato de etilo; Ácido 6-(furan-2-il)-imidazo[1,2-a]piridin-2-carboxílico; 6-(Furan-3-il)-imidazo[1,2-a]piridin-2-carboxilato de etilo, Ácido 6-(furan-3-il)-imidazo[1,2-a]piridin-2-carboxílico; 6-[5-(Hidroximetil)furan-2-il]imidazo[1,2-a]piridin-2-carboxilato de etilo, Ácido 6-{5-(hidroximetil)furan-2-il]imidazo[1,2-a]piridin-2-carboxílico, 6-(Oxazol-2-il)-imidazo[1,2-a]piridin-2-carboxilato de etilo; Ácido 6-(oxazol-2-il)-imidazo[1,2-a]piridin-2-carboxílico; 6-(1H-1,2,4-triazol-3-il)-imidazo[1,2-a]piridin-2-carboxilato de etilo, Ácido 6-(1H-1,2,4-triazol-3-il)imidazo[1,2-a]piridin-2-carboxílico, 6-(1H-1,2,3-triazol-4-il)-imidazo[1,2-a]piridin-2-carboxilato de etilo; y Ácido 6-(1H-1,2,3-triazol-4-il)imidazo[1,2-a]piridin-2-carboxílico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0800004A FR2925902B1 (fr) | 2008-01-02 | 2008-01-02 | DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070073A1 true AR070073A1 (es) | 2010-03-10 |
Family
ID=39739369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105778A AR070073A1 (es) | 2008-01-02 | 2008-12-30 | Derivados de imidazo[1, 2 - a]piridin-2-carboxamidas, intermediarios para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades que implican a los receptores not. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20100317656A1 (es) |
| EP (1) | EP2225244A1 (es) |
| JP (1) | JP2011508759A (es) |
| KR (1) | KR20100109941A (es) |
| CN (1) | CN101959886A (es) |
| AR (1) | AR070073A1 (es) |
| AU (1) | AU2008352728A1 (es) |
| BR (1) | BRPI0822223A2 (es) |
| CA (1) | CA2710797A1 (es) |
| CL (1) | CL2008003927A1 (es) |
| CO (1) | CO6331307A2 (es) |
| EA (1) | EA201070817A1 (es) |
| FR (1) | FR2925902B1 (es) |
| IL (1) | IL206673A0 (es) |
| MA (1) | MA32057B1 (es) |
| MX (1) | MX2010007351A (es) |
| PA (1) | PA8810101A1 (es) |
| PE (1) | PE20091182A1 (es) |
| TW (1) | TW200932746A (es) |
| UY (1) | UY31588A1 (es) |
| WO (1) | WO2009112651A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2925907B1 (fr) * | 2008-01-02 | 2010-10-15 | Sanofi Aventis | DERIVES DE 2-HETEROAROYL-IMIDAZO°1,2-a!PYRIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| US8809541B2 (en) * | 2010-08-25 | 2014-08-19 | Neopharm Co., Ltd. | Heterocyclic compound, and composition for treating inflammatory diseases using same |
| JP6800158B2 (ja) | 2015-02-20 | 2020-12-16 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｇｄｆ−８阻害剤 |
| PT3684767T (pt) | 2017-09-22 | 2024-07-29 | Jubilant Epipad LLC | Compostos heterocíclicos como inibidores de pad |
| CA3076476A1 (en) | 2017-10-18 | 2019-04-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| CN107915752B (zh) * | 2017-11-14 | 2018-09-18 | 牡丹江医学院 | 一种治疗白内障的药物及其制备方法 |
| AU2018372211B2 (en) | 2017-11-24 | 2023-02-02 | Jubilant Episcribe LLC, | Heterocyclic compounds as PRMT5 inhibitors |
| JP7279063B6 (ja) | 2018-03-13 | 2024-02-15 | ジュビラント プローデル エルエルシー | Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8827189D0 (en) * | 1988-11-21 | 1988-12-29 | Fujisawa Pharmaceutical Co | 2(1h)-quinolinone compounds processes for preparation thereof & pharmaceutical composition comprising same |
| US5716964A (en) * | 1989-12-04 | 1998-02-10 | G.D. Searle & Co. | Tetrazolyl substituted imidazo 1,2-a!pyridinylalkyl compounds for treatment of neurotoxic injury |
| FR2696177B1 (fr) * | 1992-09-28 | 1995-05-12 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. |
| GB0420519D0 (en) * | 2004-09-15 | 2004-10-20 | Novartis Ag | Organic compounds |
| CA2695989A1 (en) * | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
-
2008
- 2008-01-02 FR FR0800004A patent/FR2925902B1/fr not_active Expired - Fee Related
- 2008-12-23 PA PA20088810101A patent/PA8810101A1/es unknown
- 2008-12-30 AR ARP080105778A patent/AR070073A1/es unknown
- 2008-12-30 PE PE2008002195A patent/PE20091182A1/es not_active Application Discontinuation
- 2008-12-30 CL CL2008003927A patent/CL2008003927A1/es unknown
- 2008-12-30 UY UY31588A patent/UY31588A1/es not_active Application Discontinuation
- 2008-12-31 CA CA2710797A patent/CA2710797A1/fr not_active Abandoned
- 2008-12-31 CN CN2008801277688A patent/CN101959886A/zh active Pending
- 2008-12-31 TW TW097151675A patent/TW200932746A/zh unknown
- 2008-12-31 MX MX2010007351A patent/MX2010007351A/es not_active Application Discontinuation
- 2008-12-31 KR KR1020107017147A patent/KR20100109941A/ko not_active Withdrawn
- 2008-12-31 BR BRPI0822223-1A patent/BRPI0822223A2/pt not_active IP Right Cessation
- 2008-12-31 EP EP08873283A patent/EP2225244A1/fr not_active Ceased
- 2008-12-31 WO PCT/FR2008/001835 patent/WO2009112651A1/fr not_active Ceased
- 2008-12-31 EA EA201070817A patent/EA201070817A1/ru unknown
- 2008-12-31 AU AU2008352728A patent/AU2008352728A1/en not_active Abandoned
- 2008-12-31 JP JP2010541084A patent/JP2011508759A/ja not_active Withdrawn
-
2010
- 2010-06-28 IL IL206673A patent/IL206673A0/en unknown
- 2010-07-01 US US12/828,372 patent/US20100317656A1/en not_active Abandoned
- 2010-07-02 CO CO10080876A patent/CO6331307A2/es not_active Application Discontinuation
- 2010-08-02 MA MA33055A patent/MA32057B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101959886A (zh) | 2011-01-26 |
| MX2010007351A (es) | 2010-10-05 |
| US20100317656A1 (en) | 2010-12-16 |
| WO2009112651A1 (fr) | 2009-09-17 |
| PA8810101A1 (es) | 2009-08-26 |
| FR2925902A1 (fr) | 2009-07-03 |
| KR20100109941A (ko) | 2010-10-11 |
| UY31588A1 (es) | 2009-08-03 |
| CO6331307A2 (es) | 2011-10-20 |
| IL206673A0 (en) | 2010-12-30 |
| EA201070817A1 (ru) | 2011-02-28 |
| EP2225244A1 (fr) | 2010-09-08 |
| PE20091182A1 (es) | 2009-08-31 |
| TW200932746A (en) | 2009-08-01 |
| JP2011508759A (ja) | 2011-03-17 |
| CL2008003927A1 (es) | 2010-02-12 |
| BRPI0822223A2 (pt) | 2015-06-23 |
| AU2008352728A1 (en) | 2009-09-17 |
| MA32057B1 (fr) | 2011-02-01 |
| FR2925902B1 (fr) | 2011-01-07 |
| CA2710797A1 (fr) | 2009-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070073A1 (es) | Derivados de imidazo[1, 2 - a]piridin-2-carboxamidas, intermediarios para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades que implican a los receptores not. | |
| JP7149276B2 (ja) | Ｐｄ－ｌ１内在化誘導物質としてのテトラヒドロイミダゾ［４，５－ｃ］ピリジン誘導体 | |
| ES2555167T3 (es) | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa | |
| JP6162904B2 (ja) | 新規複素環式化合物 | |
| ES2664985T3 (es) | Compuestos y métodos para modulación de quinasa, e indicaciones de los mismos | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| ES2710190T3 (es) | Derivados de 4-azaindol | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| KR20180094976A (ko) | Tank-결합 키나제 억제제 화합물 | |
| AR068057A1 (es) | Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. | |
| EA201000615A1 (ru) | Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы) | |
| AR086676A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa | |
| JP2023021316A (ja) | ピリジンアミン－ピリドンおよびピリミジンアミン－ピリドン化合物 | |
| MX2012005284A (es) | Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello. | |
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| NZ597533A (en) | Apoptosis signal-regulating kinase inhibitors | |
| EA201400701A1 (ru) | Замещенные соединения пиразоло[1,5-a]пиридина в качестве ингибиторов тропомиозинрецепторной киназы (trk) | |
| AR081994A1 (es) | Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR081252A1 (es) | Compuestos para el tratamiento del sindrome metabolico | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| AR086143A1 (es) | Derivados de imidazopiridina como inhibidores de pi3k | |
| AR035858A1 (es) | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 | |
| AR087841A1 (es) | Derivados de tetrahidrotriazolopirimidina | |
| AR065531A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |